Novartis Issues Voluntary Nationwide Recall Of One Lot Of Sandimmune Oral Solution, 100 mg/mL Due To Crystallization
Portfolio Pulse from Benzinga Newsdesk
Novartis has issued a voluntary nationwide recall of one lot of Sandimmune Oral Solution, 100 mg/mL due to crystallization. The recall is expected to impact the company's revenues and reputation in the short term.
September 11, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novartis' recall of Sandimmune Oral Solution may negatively impact its revenues and reputation in the short term.
The recall of a product, especially one that is nationwide, often leads to a decrease in sales and can damage the company's reputation. This can lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100